Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking

Pharmacogenetics and Genomics

Volumn 22, Issue 2, 2012, Pages 143-151

  Dobrinas, Maria ^a   Cornuz, Jacques ^b   Pedrido, Leticia ^a   Eap, Chin B ^a,c  

^a Hopital de Cery   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

cytochrome P450 oxidoreductase; cytochrome P4501A2; genetic polymorphism; inducibility; POR; smoking

Indexed keywords

ALANINE; CAFFEINE; CYSTEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 REDUCTASE; GLYCINE; PARAXANTHINE; THREONINE;

ADULT; ARTICLE; CIGARETTE SMOKING; ENZYME ACTIVITY; FEMALE; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN INDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION;

ADULT; CAFFEINE; CYTOCHROME P-450 CYP1A2; ENZYME INDUCTION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; SMOKING; SMOKING CESSATION;

EID: 84855975450     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834e9e1a     Document Type: Article

References (32)

1. Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010; 42:268-354.
2. Gunes A, Dahl ML. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008; 9:625-637. (Pubitemid 351803920)
3. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005; 97:125-134. (Pubitemid 41291208)
4. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007; 64:1917-1921. (Pubitemid 47462906)
5. Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of the CYP1A2 gene. J Clin Psychopharmacol 2004; 24:214-219. (Pubitemid 38380846)
6. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23:119-127. (Pubitemid 36368788)
7. Spigset O, Carleborg L, Hedenmalm I, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995; 58:399-403.
8. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005; 27:539-543. (Pubitemid 41098833)
9. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011; 90:117-125.
10. Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo MG, Zengil H, et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 2009; 10: 769-778.
11. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007; 63:537-546. (Pubitemid 46684487)
12. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999; 125: 803-808. (Pubitemid 29192503)
13. Sachse C, Brockmö ller J, Bauer S, Roots I. Functional significance of a C-> A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47:445-449. (Pubitemid 29161279)
14. Hubbard PA, Shen AL, Paschke R, Kasper CB, Kim JJ. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J Biol Chem 2001; 276:29163-29170.
15. Masters BS. The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases. Biochem Biophys Res Commun 2005; 338: 507-519. (Pubitemid 41540597)
16. Agrawal V, Huang N, Miller WL. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 2008; 18:569-576.
17. Oneda B, Crettol S, Jaquenoud Sirot E, Bochud M, Ansermot N, Eap CB. The P450 oxidoreductase is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 2009; 19:877-883.
18. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 2008; 105:1733-1738. (Pubitemid 351346583)
19. Sandee D, Morrissey K, Agrawal V, Tam HK, Kramer MA, Tracy TS, et al. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 2010; 20:677-686.
20. Gomes AM,Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 2009; 10:579-599.
21. Fluck CE, Pandey AV. Clinical and biochemical consequences of p450 oxidoreductase deficiency. Endocr Dev 2011; 20:63-79.
22. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4:109-116. (Pubitemid 24210928)
23. Huang N, Pandey AV, Agrawal V, ReardonW, Lapunzina PD, Mowat D, et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005; 76:729-749. (Pubitemid 40563096)
24. Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, Sato N, et al. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 2005; 90:414-426. (Pubitemid 40116690)
25. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, Zhong XB. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 2008; 18: 11-24. (Pubitemid 351161645)
26. Fluck CE, Mullis PE, Pandey AV. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem Biophys Res Commun 2010; 401:149-153.
27. R Development Core Team. R: a language and environment for statistical computing, R Fondation for Statistical Computing, Vienna, Austria. 2010. www.r-project-org.
28. National Center for Biotechnology Information-dbSNP. 2011. www.ncbi.nlm.nih.gov.
29. Miller WL, Agrawal V, Sandee D, Tee MK, Huang N, Choi JH, et al. Consequences of POR mutations and polymorphisms. Mol Cell Endocrinol 2011; 336:174-179.
30. Shen AL, O'Leary KA, Kasper CB. Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 2002; 277: 6536-6541. (Pubitemid 34968452)
31. Otto DM, Henderson CJ, Carrie D, Davey M, Gundersen TE, Blomhoff R, et al. Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 2003; 23:6103-6116. (Pubitemid 37013089)
32. Henderson CJ, Otto DM, Carrie D, Magnuson MA, Mclaren AW, Rosewell I, et al. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003; 278:13480-13486. (Pubitemid 36800122)